Engineered NKG2C <sup>+</sup> NK-like T cells exhibit superior antitumor efficacy while mitigating cytokine release syndrome
Kyle B. Lupo(Memorial Sloan Kettering Cancer Center), Katharine C. Hsu(Memorial Sloan Kettering Cancer Center)
Cited by 2
Related Papers
synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
|Nature Communications|2024|39